文献速递骨软组织肉瘤与黑色素瘤

靶向GM2、GD2和GD3的三价神经节苷脂疫苗联合免疫佐剂OPT-821对比单用OPT-821在转移性肉瘤术后无病患者中的随机II期试验

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.
PubMed 文献 · Eur J Cancer · 2022-10-08

该随机II期试验将136例转移性肉瘤完全转移灶切除术后无病患者随机分为疫苗联合OPT-821组和单用OPT-821组,每组68例。疫苗组第9周血清学应答率96.5%显著高于佐剂组32.8%,但1年无复发生存率(34.5% vs 34.8%,P=0.725)和1年总生存率(93.1% vs 91.5%,P=0.578)两组无差异。

要点

  • 疫苗组第9周血清学应答率96.5%,佐剂组32.8%,组间差异持久。
  • 1年无复发生存率疫苗组34.5% vs 佐剂组34.8%,P=0.725,无差异。
  • 1年总生存率疫苗组93.1% vs 佐剂组91.5%,P=0.578,无差异。

核心结论

  • 疫苗可诱导持续的血清学应答,但两组无复发生存率和总生存率无差异。

研究设计与样本

  • 随机II期试验,纳入转移性肉瘤完全转移灶切除术后无病患者136例,每组68例。
  • 疫苗组接受KLH偶联的靶向GM2、GD2和GD3神经节苷脂疫苗联合免疫佐剂OPT-821,对照组单用OPT-821。
  • 患者在第1、2、3、8、16、28、40、52、68和84周接受10次皮下注射,并随访复发证据。
  • 主要终点为无复发生存率,次要终点包括总生存率和血清学应答。

主要发现

  • 患者平均年龄51.2岁,男性占52.2%,90.4%有复发疾病,86.8%为高级别肿瘤,14%切除≥4个转移灶。
  • 组织学类型包括平滑肌肉瘤(33%)、梭形细胞肉瘤(14%)、未分化多形性肉瘤(13%)、骨肉瘤(10%)、滑膜肉瘤(9%)、脂肪肉瘤(9%)和其他(12%)。
  • 大多数不良事件为Grade ≤2(疫苗组83.8%,佐剂组70.6%);疫苗组最常见(≥20%患者)为注射部位反应(89.7%)、乏力(44.1%)和发热(27.9%),单用佐剂组为注射部位反应(69.1%)。
  • 1年无复发生存率疫苗组34.5% vs 佐剂组34.8%,P=0.725;1年总生存率疫苗组93.1% vs 佐剂组91.5%,P=0.578。
  • 第9周血清学应答率疫苗组96.5% vs 佐剂组32.8%,组间差异持久。

关键数值与推荐

  • 1年无复发生存率:疫苗组34.5% vs 佐剂组34.8%,P=0.725。
  • 1年总生存率:疫苗组93.1% vs 佐剂组91.5%,P=0.578。
  • 第9周血清学应答率:疫苗组96.5% vs 佐剂组32.8%。
  • 不良事件Grade ≤2比例:疫苗组83.8% vs 佐剂组70.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrence after resection of metastatic sarcoma is common. The gangliosides GM2, GD2 and GD3 are strongly expressed across sarcoma subtypes. We hypothesised that generation of anti-ganglioside antibodies would control micrometastases and improve outcomes in sarcoma patients who were disease-free after metastasectomy. METHODS: We conducted a randomised phase II trial of the immunological adjuvant OPT-821 with a KLH-conjugated ganglioside vaccine targeting GM2, GD2 and GD3, versus OPT-821 alone in patients with metastatic sarcoma following complete metastasectomy. Patients received 10 subcutaneous injections at Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84 and were followed for evidence of recurrent disease. The primary end-point was relapse-free survival. Secondary end-points included overall survival and serologic response. RESULTS: A total of 136 patients were randomised, 68 to each arm. The mean age was 51.2, 52.2% were male, 90.4% had relapsed disease, 86.8% had high-grade tumours and 14% had ≥4 metastases resected. Histologies included leiomyosarcoma (33%), spindle cell sarcoma (14%), undifferentiated pleomorphic sarcoma (13%), osteosarcoma (10%), synovial sarcoma (9%), liposarcoma (9%) and others (12%). Most adverse events were Grade ≤2 (83.8% and 70.6% in the vaccine and adjuvant arms, respectively). The most common (≥20% of patients) were injection site reaction (89.7%), fatigue (44.1%) and pyrexia (27.9%) on the vaccine arm, and injection site reaction (69.1%) on the adjuvant only arm. The 1-year relapse-free survival rate (34.5% and 34.8% in the vaccine and OPT-821 monotherapy arm, respectively) did not differ between arms (P = 0.725). One-year overall survival rates were 93.1% and 91.5% in the vaccine and OPT-821 monotherapy arm, respectively (P = 0.578). Serologic responses at week 9 were more frequent on the vaccine arm (96.5% of patients) than in the adjuvant arm (32.8%), and the difference between groups was durable. CONCLUSIONS: A sustained serologic response to vaccination was induced with the vaccine, but no difference in recurrence-free or overall survival was observed between treatment arms. CLINICALTRIALS: gov identifier: NCT01141491.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rosenbaum E, Chugh R, Ryan CW, et al. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer. 2022. PMID: 36215947. doi:10.1016/j.ejca.2022.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。